SJSoo-Im Jang

Soo-Im Jang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soo-Im Jang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility and Safety of Elexir, an External Trigeminal Nerve Electrical Stimulator for the Acute Treatment of Migraine

    by Soo-Im Jang, Soohyun Cho, Mi Ji Lee

    Purpose: External trigeminal nerve stimulation (eTNS) is a noninvasive neuromodulation technique used to treat migraine. This study evaluated the feasibility and safety of Elexir®, a newly developed eTNS device, for the acute treatment of migraine at home.Methods: This prospective, randomized, sham-controlled postmarketing study enrolled participants with migraine who reported 2–8 attacks per month. Participants were assigned 1:1 to verum or sham stimulation and instructed to use Elexir® at home for 60 minutes during an eligible migraine attack. Feasibility of home use was assessed in terms of per-protocol use and treatment completion at both the participant and session levels; session completion was defined by 60 (±5)-minute stimulation recorded in the device log. Assessments also included adverse events (AEs) and exploratory efficacy outcomes: changes in pain intensity, pain freedom and relief, and resolution of associated symptoms.Results: Of the 100 randomized participants, 79 formed the home-use population. Within this population, 78 (98.7%; 95% confidence interval [CI], 93.2%–99.8%) used Elexir® during an eligible migraine attack, and 75 (94.9%; 95% CI, 87.7%–98.0%) completed at least one session. Of the 139 treatment sessions conducted at home, 103 (74.1%; 95% CI, 66.2%–80.7%) were completed within the protocol-defined duration. Ten participants (10.0%) reported AEs and eight participants (8.0%) reported device-related AEs. No serious device-related AEs were observed. The groups did not differ significantly in exploratory efficacy outcomes.Conclusion: These findings support the feasibility of using Elexir® for the acute treatment of migraine; no serious device-related AEs were observed. Further studies are required to support efficacy.

  • Open Access

    Diagnostic Value of Flow-Void Sign for Localizing Ventral Dural Defects in Spine MRI

    by Soo-Im Jang, Soyoun Choi, Seung Ae Kim, Hoe Jong Jeong, Ja-Young Choi, Mi Ji Lee

    Jang SI, et al. J Clin Neurol. 2026 ;22:e34. https://doi.org/10.3988/jcn.2025.0618

  • Association Between Obesity and the Risk of Migraine

    by Soo-Im Jang, Namoh Kim, Kyungdo Han, Mi Ji Lee

    Although obesity is recognized as a risk factor of migraine chronification, its longitudinal impact on migraine onset remains unclear. The aim of this study was to investigate the association between obesity and the risk of developing migraine in a longitudinal setting. We conducted a population-based prospective cohort study using data from the Korean National Health Insurance Service. Individuals aged 20-39 years who underwent health examinations between 2009 and 2012 were enrolled, excluding those with a history of migraine, missing data, or a migraine diagnosis within the first year. Participants were followed to the end of 2018. Body mass index (BMI) was categorized into 5 groups and waist circumference (WC) into 6 levels. Outcome was the first migraine claim (International Classification of Diseases, Tenth Revision code G43). We evaluated the associations of BMI and WC with the risk of migraine using multivariable Cox proportional hazard regression models. Interaction analyses were conducted based on demographic and lifestyle factors. Among 6,106,560 individuals included (mean age: 30.6 ± 4.98 years; 39% female), the risk of migraine increased with increasing BMI (adjusted hazard ratio [aHR] 1.001 [95% CI 0.991-1.010], 1.047 [95% CI 1.040-1.055], 1.087 [95% CI 1.079-1.094], and 1.121 [95% CI 1.106-1.136] for underweight, overweight, stage 1 obesity, and stage 2 obesity, respectively, compared with normal BMI) and WC (aHR 0.913 [95% CI 0.906-0.921], 0.969 [95% CI 0.960-0.978], 1.022 [95% CI 1.010-1.034], 1.048 [95% CI 1.032-1.065], and 1.048 [95% CI 1.030-1.067] for levels 1, 2, 4, 5, and 6, respectively, compared with level 3). This dose-dependent relationship remained significant for WC after adjusting for BMI, but not vice versa. A stronger association between abdominal obesity and migraine risk was observed in younger individuals (p for interaction = 0.0181), nonsmokers (p for interaction = 0.0341), and heavy drinkers (p for interaction = 0.0143). Obesity was associated with an increased risk of migraine in young adults in a dose-dependent manner, with WC demonstrating a more robust independent association than BMI. Owing to the limitations of claims data, our study needs cautious interpretation and further validation in studies with detailed clinical information.


  • Open Access

    Refractory Bell’s palsy responding to late treatment with high-dose intravenous steroids

    by Baul Kim, Soo-Im Jang, Soo-Hyun Park, Nam-Hee Kim

    Bell’s palsy is an acute peripheral facial paralysis with no detectable cause. Although the prognosis of Bell’s palsy is generally good, some patients experience poor recoveries and there is no established treatment for those that do not recover even after receiving the conventional treatment. Here we present two cases of refractory Bell’s palsy with facial nerve enhancement in magnetic resonance imaging who showed symptomatic improvement after the late administration of high-dose intravenous methylprednisolone.